Hernia Repair Devices Market is Set to Attain Valuation of US$ 6.57 Billion by 2033
Hernia repair devices market is experiencing strong growth momentum driven by rising procedural volumes, technological advancements in mesh and robotic systems, and increasing adoption of minimally invasive techniques across both developed and emerging regions.
Chicago, June 25, 2025 (GLOBE NEWSWIRE) -- The global hernia repair devices market was valued at US$ 4.69 billion in 2024 and is projected to reach US$ 6.57 billion by 2033, growing at a CAGR of 4.32% during the forecast period 2025–2033.
Global physicians performed nearly 40 million hernia repairs in 2024, according to the International Hernia Society, underscoring an epidemiological load that directly feeds the hernia repair devices market. Abdominal-wall weakness is amplified by rising obesity, rapid urbanization, and strenuous occupations, leading to earlier presentation of inguinal and incisional defects. In the United States alone, procedure volumes climbed above 1.1 million last year, while Asia-Pacific hospitals are quickly closing that gap as ageing populations swell. Improved diagnostic outreach in Brazil, India, and Nigeria lifts latent incidence into surgical theatres, creating a rare consistency in risk-factor universality that is largely unaffected by cultural nuances. Seasoned surgeons at Cleveland Clinic confirm that emergency admissions remain proportional to elective bookings, signaling that supply expansion must run parallel to prevention initiatives to tame hospital bed occupancy.
Download Sample Pages:
While incidence drives baseline demand, referral patterns set the gradient of device utilization. Private-insurance penetration in Germany and Australia now reimburses outpatient mesh repair, shifting operations from public inpatient wards to ambulatory centers equipped with lighter fixation instruments. Conversely, large government camp programs in Vietnam distribute pre-sterilized polypropylene plugs to district surgeons, creating a two-tiered yet interconnected ecosystem for the hernia repair devices market. Both channels rely on supply-chain resilience; pandemic-era shortages still echo in Mexico, where delayed shipments doubled surgical waitlists last winter. To buffer regional demand shocks, manufacturers are decentralizing production, with new molding facilities announced in Gujarat and North Carolina during 2024.
Key Findings In Hernia Repair Devices Market
Market Forecast (2033)
US$ 6.57 billion
CAGR
4.32%
Largest Region (2024)
North America (51%)
By Product Type
Hernia Mesh (77%)
By Surgery Type
Inguinal Hernia (67%)
By Procedure Type
Open Surgery (77%)
Top Drivers
Rising hernia prevalence boosts demand for repair devices
Aging population increases need for hernia surgical solutions
Growing adoption of minimally invasive devices drives market
Top Trends
Bioabsorbable meshes gain traction for safer hernia repairs
Robotic-assisted hernia surgeries enhance precision and recovery speed
Lightweight synthetic meshes reduce complications in hernia procedures
Top Challenges
High costs of advanced hernia devices limit accessibility
Post-surgical complications with meshes challenge market trust
Stringent regulatory approvals delay hernia device innovations
Shift Toward Mesh Implants Dominates Current Surgical Preference Globally Today
Modern guidelines from the European Hernia Society unequivocally recommend tension-free mesh placement for most primary abdominal-wall defects, a view echoed by the Americas Hernia Society in its 2024 update. This convergence has triggered brisk expansion of lightweight synthetic meshes, which now represent the majority of consumables shipped to U.S. and Japanese hospitals. Clinicians favor macroporous, monofilament constructions because these materials integrate rapidly with surrounding fascia and reduce chronic-pain complaints. Purchasing committees grappling with readmission penalties increasingly note that mesh stability correlates with lower re-operation rates, making quality-of-life data an influential deal driver.
In the hernia repair devices market, mesh suppliers are segmenting portfolios into disease-specific SKUs such as pre-shaped umbilical patches or anatomically contoured inguinal panels. BD's Phasix ST and Medtronic's ProGrip Laparoscopic achieve fixation without additional tacks, trimming surgery time by nearly ten minutes in multicenter trials published early 2024. Emerging companies like TELA Bio highlight hybrid polymer-collagen constructions to attract surgeons concerned about foreign-body reaction. As procurement teams deploy sophisticated total-cost models, value propositions now hinge on postoperative quality metrics rather than mere product lifespan, further professionalizing purchase decisions within the hernia repair devices market.
Open Versus Laparoscopic Repair Competition Encourages Continuous Technology Refinements Worldwide
Open repair, epitomized by the Lichtenstein technique, remains indispensable in rural settings where laparoscopy infrastructure is sparse; nonetheless, minimally invasive adoption is rising steadily in tertiary centers. The United Kingdom's National Hernia Audit logged more than 137,000 laparoscopic inguinal procedures in 2024, surpassing open cases for the first time. This tension is reverberating through the hernia repair devices market, as surgeons cite smaller incisions, faster ambulation, and fewer wound complications as key advantages. Yet steep learning curves and capital cost still restrain diffusion in low-income nations, creating a dual pathway in which both modalities evolve in parallel rather than sequentially.
Instrument vendors are responding vigorously. Within the hernia repair devices market, laparoscopic trocars now integrate smoke evacuation, while open-repair kits bundle self-adhesive mesh and ergonomic retractors. Ethicon's new Harmonic 1100 shears deliver lower thermal spread for safer dissection near cord structures, and Medtronic has updated its Versaport trocars with blunt entry technology to reduce port-site bleeding. Such incremental upgrades, stimulated by modality competition, enable hospitals to match technology selections with surgeon skill sets and case complexity, achieving better outcomes without disruptive platform shifts.
Robotic Platforms Gain Traction By Reducing Operative Fatigue And Recurrence
Within the hernia repair devices market, robotic surgery reached a milestone in 2023 when Intuitive Surgical received FDA clearance for transabdominal pre-peritoneal repair on its da Vinci X. Since then, more than 650 U.S. centers have logged routine robotic ventral cases, according to Premier surgery registries. Robots provide wristed articulation inside narrow planes, allowing broader mesh placement with uniform overlap, an action linked to fewer recurrences in Cleveland Clinic's 2,500-patient analysis released April 2024. Console ergonomics also reduce musculoskeletal strain for surgeons performing multiple cases per day, creating a human-factor incentive that traditional laparoscopy lacks.
The hernia repair devices market quickly adjusted; companies introduced mesh loaders compatible with multi-port robotic arms and launched longer absorbable barbed sutures that obviate knot-tying. CMR Surgical's Versius entered Canadian hospitals in February 2024 with a tailored ventral-hernia package, while Moon Surgical's Maestro targets outpatient centers with a smaller footprint and disposable articulating instruments. Administrators cite real-world evidence showing median hospital stays below 24 hours after robotic repair, a benchmark previously limited to laparoscopy centers of excellence, strengthening the business case for robotic expansion.
Biologic and Biosynthetic Materials Address Infection Concerns In Complex Cases
Within the hernia repair devices market, contaminated fields such as strangulated hernias or previous mesh infections demand materials that resist colonization. Biologic grafts derived from porcine or bovine dermis preserve extracellular-matrix architecture, enabling native-cell repopulation and limiting biofilm formation. More than 42,000 of these implants were distributed in North America during 2023, based on Vizient supply-chain data, though higher cost and variable strength historically limited widespread uptake.
Biosynthetic offerings now deliver intermediate performance at a lower price than dermal matrices. In the hernia repair devices market, products like Gore Bio-A and Phasix absorb over six to eighteen months, maintaining tensile support during critical healing without permanent residue. Randomized trials presented at the 2024 American College of Surgeons meeting demonstrated recurrence rates comparable to permanent mesh at two-year follow-up in contaminated ventral repairs, reigniting debate over routine prophylactic use in high-risk obesity cohorts. Surgeons at Mayo Clinic increasingly deploy hybrid meshes comprising poly-4-hydroxybutyrate fibers intertwined with ovine collagen to balance strength, pliability, and infection resistance.
Regulatory Decisions And Reimbursement Policies Shape Innovation and Adoption Pathways
Heightened post-market scrutiny following the 2019 withdrawal of certain composite meshes continues to influence the hernia repair devices market in 2024. The FDA now requires five-year registry data before granting broader indications, prompting developers to embed real-world-evidence platforms such as Blue Cloud early in trials. Simultaneously, the European Union's Medical Device Regulation tightens labelling and traceability, driving multinational firms to harmonize unique device identifiers across packaging to prevent distribution bottlenecks.
Financial incentives are equally pivotal. Japan's April 2024 fee schedule rewards procedures that document opioid-sparing anesthesia, indirectly favoring mesh systems with atraumatic fixation. Germany introduced a diagnosis-related-group add-on for biosynthetic implants in complex repairs, narrowing cost gaps that previously slowed uptake. These levers reverberate across the hernia repair devices market, compelling manufacturers to bundle outcome data with economic analyses when pitching to value committees. In parallel, Brazil's ANVISA launched an accelerated pathway for domestically produced polypropylene mesh, boosting local innovation and intensifying competition within the market.
Competitive Landscape Shifts With Strategic Acquisitions and Surgeon Training Alliances
Consolidation remains a defining feature of surgical implants, and the hernia repair devices market is no exception. Medtronic's July 2024 acquisition of AiM Medical Robotics' soft-tissue navigation unit aims to embed augmented-reality guidance into ventral-hernia workflows. Earlier, Coloplast purchased TissueLink, owner of patented self-gripping-patch technology that shortens fixation time, reflecting a wider movement toward solution suites rather than single-use products.
Education-centric partnerships evolve in parallel. Johnson & Johnson's Ethicon division renewed its alliance with the American Hernia Society to support simulation-based modules covering open, laparoscopic, and robotic techniques; 4,800 surgeons in 18 countries have already completed the curriculum. Gore, meanwhile, livestreams cadaver labs through a subscription portal, allowing rural physicians to stay current on evolving devices. Robust training ecosystems expand addressable demand because confident surgeons more readily adopt advanced implants, intensifying rivalry inside the hernia repair devices market.
Modify Report as Per Requirements:
Future Outlook Highlights Personalized Devices and Data-Driven Postoperative Monitoring Advances
Patient-specific solutions headline the next innovation cycle. Three-dimensional printed mesh cut to exact defect geometry has already been implanted in more than 600 European cases through collaborations with Materialise and Belgian university hospitals; imaging follow-up shows superior conformity and reduced seroma volume. Concurrently, sensor-embedded sutures transmitting tension data to clinicians are in pilot trials at Stanford, aligning with the hernia repair devices market's gradual migration toward precision surgery.
Postoperative surveillance is also digitizing. Wearable patches monitoring core activity can flag abnormal strain that threatens repair integrity, while telehealth portals automatically schedule video check-ins when thresholds are exceeded. Australia's My Health Record now integrates hernia-repair metadata, enabling nationwide effectiveness assessments without manual audits. As payers begin recognising remote-monitoring value, manufacturers are bundling apps and cloud analytics alongside physical implants. These converging trends will transform the hernia repair devices market from product-centric transactions into longitudinal data partnerships that continuously refine surgical practice.
Global Hernia Repair Devices Market Major Players:
B Braun Melsungen AG
Cook Medical
Medtronic Plc
W.L. Gore & Associates
Ethicon Inc.
C.R Bard Inc.
Atrium
LifeCell Corporation
Baxter International
Hernia mesh S.R.L.
Other Prominent Players
Key Segmentation:
By Product Type
Hernia Mesh
Biologic Mesh
Synthetic Mesh
Hernia Fixation Devices
Sutures
Tack Applicators
Glue Applicators
By Surgery Type
Inguinal Hernia
Umbilical Hernia
Incisional Hernia
Femoral Hernia
Others
By Procedure Type
Open Surgery
Laparoscopic Surgery
By Region
North America
Europe
Asia Pacific
Middle East & Africa (MEA)
South America
Explore Report Details Before You Buy:
About Astute Analytica
Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements.
With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace.
Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@astuteanalytica.comWebsite: https://www.astuteanalytica.com/ Follow us on: LinkedIn | Twitter | YouTube
CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@astuteanalytica.com Website: https://www.astuteanalytica.com/

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
21 minutes ago
- Bloomberg
New Zealand Māori Party MP Takutai Kemp Dies Aged 50
New Zealand member of parliament Takutai Moana Natasha Kemp, of the small opposition Māori Party, has died at the age of 50. Kemp, who reportedly had kidney disease, represented the Māori electorate of Tāmaki Makaurau in Auckland. She died in the early hours of Thursday morning, the Māori Party said in a statement.


Business Upturn
an hour ago
- Business Upturn
Amesite's HIPAA Compliant NurseMagic™ App Now Operates in 16 Languages — Expanding Access to AI-Powered Charting for Nearly 1 Million U.S. Nurses
By GlobeNewswire Published on June 26, 2025, 01:43 IST DETROIT, June 25, 2025 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, today announced that its flagship app, NurseMagic™, now supports charting in 16 languages. This major enhancement is designed to address a key barrier to success for nearly 1 million nurses in the U.S. who speak English as a second language (ESL) — accounting for 19.2% of the nursing workforce — and to chart more efficiently and with greater confidence. This multilingual capability positions Amesite to meet immediate market needs. Markets now able to leverage the platform include: ESL nurses in the United States : Nearly 20% of U.S. nurses have English as a Second Language (ESL) : Nearly 20% of U.S. nurses have English as a Second Language (ESL) International healthcare systems treating U.S. patients : There are over 6.5 Million nurses in the top 10 medical tourist destinations for U.S. patients alone. : There are over 6.5 Million nurses in the top 10 medical tourist destinations for U.S. patients alone. Private clinics in multilingual regions: The private sector provides nearly 40% of all healthcare in PAHO, AFRO, and WPRO regions, 57% in SEARO, and 62% in EMRO. Madison Bush, Director of Corporate Operations, said, 'This rollout reflects our disciplined approach to targeting segments with clear, documented needs — including the nearly one in five nurses in the U.S. who speak English as a second language. By addressing the needs of this workforce, who must document in English, we're positioned to capture value domestically and expand internationally.' Sai Nittala, Senior AI Manager, said, 'NurseMagic™ V3.0 delivers healthcare charting solutions that outperform generic, off-the-shelf AI tools. Unlike many unregulated or non-integrated solutions, NurseMagic™ is designed for seamless integration into critical healthcare workflows — where compliance, accuracy, and efficiency are essential. Our multilingual capability underscores our ability to scale rapidly while meeting real-world needs.'' Dr. Ann Marie Sastry, Founder & CEO, said, 'We have growing B2B traction following our launch of enterprise administration tools, and are also supporting B2C growth in new segments that prepare us for global expansion. As reported in our Q3 2025 10‑Q, we achieved a 2.4× quarter-on-quarter revenue increase while continuing to cut operating expenses. We believe we're on track for further revenue growth and cost efficiencies in coming quarters.' NurseMagic™ is Now Available In: English, Chinese, Hindi, Spanish, French, Portuguese, Russian, Indonesian, German, Japanese, Korean, Turkish, Italian, Ukrainian, Dutch, Swedish. Amesite recently announced a 2.4x quarter-over-quarter revenue increase in its 10-Q filing, driven by rapid adoption of its NurseMagic™ platform and improvements in operating efficiency. The company also launched a higher-priced enterprise tier in response to growing B2B demand for more capacity. In April, Amesite reported that NurseMagic™ meets HIPAA requirements for individual users and enterprises, enabling secure documentation of protected health information across all user types. About Amesite Inc. Amesite (NASDAQ: AMST) is an AI-driven company with an immediate aim to transform the $330 billion home and healthcare segments. Its flagship product, NurseMagic™, streamlines documentation for nurses and caregivers, reducing the time required from 20 minutes to just 20 seconds. NurseMagic™ is used by over 100 professions to improve care, enhance operational efficiency and improve financial performance. Built on proprietary AI trained on industry-specific data, NurseMagic meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages. Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning the Company, the Company's planned online machine learning platform, the Company's business plans, any future commercialization of the Company's online learning solutions, potential customers, business objectives and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'believe,' 'intend,' 'look forward,' and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement. Risks facing the Company and its planned platform are set forth in the Company's filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations [email protected] Sources Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.


Business Upturn
an hour ago
- Business Upturn
Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act
WASHINGTON, June 25, 2025 (GLOBE NEWSWIRE) — The Coalition to Improve Access to Cancer Care (CIACC) applauds the reintroduction of the Cancer Drug Parity Act, bipartisan legislation that would require group and individual health insurance plans to cover oral and self-administered anticancer medications on terms no less favorable than those covering intravenous (IV), injected, or port-administered therapies. The bill aims to eliminate outdated insurance practices that make it more expensive for patients to access self-administered cancer treatments, even when those treatments are the most appropriate or only option available. 'Patients should not face higher costs simply because their cancer treatment comes in a pill instead of an IV,' said Danielle Doheny, Director of Public Policy and Advocacy at the International Myeloma Foundation, who leads the Coalition to Improve Access to Cancer Care. 'This legislation ensures that treatment decisions are guided by what is medically best for the patient and not by outdated insurance structures that create unnecessary financial barriers for patients.' 'The lymphoma community has witnessed incredible advancement in the treatment of the disease through the development of innovative and effective therapies, including oral treatments. The Cancer Drug Parity Act seeks to protect patient access to the cancer treatments prescribed by their doctors; we support the reintroduction of this legislation on behalf of the patients and families we exist to serve,' said Meghan Gutierrez, Chief Executive Officer, Lymphoma Research Foundation. Traditionally, IV cancer drugs are covered under a health plan's medical benefit, often resulting in lower out-of-pocket costs for patients. In contrast, oral and self-administered cancer drugs are typically covered under the pharmacy benefit, where patients may face high copays, coinsurance, or deductibles. The Cancer Drug Parity Act would correct this imbalance by requiring parity in how insurers cover and reimburse cancer treatments, regardless of how they are administered. 'This bill provides us another valuable tool to mitigate the significant and burdensome out-of-pocket medical expenses facing individuals with a cancer diagnosis,' said Joanna Fawzy Doran, Esq., CEO of Triage Cancer. 'Oral therapies are sometimes not only the best option but the only option for a patient, especially those living with metastatic breast cancer. Unfortunately, they remain out of reach for many,' said Molly Guthrie, Vice President of Policy & Advocacy at Susan G. Komen. 'Treatment decisions should be determined by a patient and their provider, not dictated by outdated insurance coverage benefit design. Komen is proud to support the Cancer Drug Parity Act, ensuring breast cancer patients have the ability to choose the best treatment for them without unneeded barriers.' Healthcare providers echo the concern that patients should not face financial hardship simply because the most effective or convenient drug is in pill form. 'As providers, we have seen tremendous progress in cancer treatments, and the Cancer Drug Parity Act would protect patients' access to the treatments their oncologists prescribe. By ensuring that patient cost sharing for oral anticancer drugs is no less favorable than for IV chemotherapy, this bill would help remove one financial barrier to care and ensure patients get the right treatment,' said Robert Mancini, PharmD, BCOP, FHOPA, President of the Hematology/Oncology Pharmacy Association. Jessica MacIntyre, DNP, MBA, APRN, AOCNP®, FAANP, President of the Oncology Nursing Society, emphasized the importance of equitable access to modern therapies: 'The Oncology Nursing Society strongly supports the reintroduction of the Cancer Drug Parity Act. This legislation is crucial in ensuring that patients have equitable access to lifesaving cancer treatments regardless of the administration method. By eliminating the disparity between oral and intravenous cancer drug coverage, we can improve patient outcomes, reduce financial burdens, and advance the overall quality of cancer care. ONS is proud to stand with our coalition partners in advocating for this important bill.' Leading cancer advocacy organizations have also reaffirmed their support. 'The Cancer Drug Parity Act would help protect patients' access to their prescribed cancer treatments. By ensuring that patient cost sharing is no more burdensome for oral anticancer drugs than it is for IV anticancer drugs, the bill would remove one of the many financial barriers to care and help ensure patients get the right treatment at the right time. We strongly support this legislation and urge Congress to pass it as soon as possible,' said Association for Clinical Oncology (ASCO) Board Chair Lynn M. Schuchter, MD, FASCO. The Association of American Cancer Institutes (AACI) includes the Cancer Drug Parity Act among its public policy priorities and supports its reintroduction in Congress. This legislation is critical for eliminating financial barriers and reducing health disparities that limit patients' access to cancer care. Lisa Lacasse, President of the American Cancer Society Cancer Action Network, further underscored the bill's impact: 'Disparities in out-of-pocket costs for oral cancer treatments can impact patient and physician decision-making and can lead to patients forgoing the best treatment for their disease. Many patients prefer, when appropriate, chemotherapies that are available in pill form because it is easier to administer and can allow them to have a better quality of life. The Cancer Drug Parity Act would equalize out-of-pocket costs for cancer drugs, whether they're taken orally or delivered intravenously. We urge Congress to advance this lifesaving, bipartisan legislation.' For lung cancer patients, oral targeted therapies have become a cornerstone of treatment. 'The Cancer Drug Parity Act puts patients first,' said Laurie Ambrose, President and CEO of GO2 for Lung Cancer. 'This legislation would ensure that healthcare plans covering cancer treatments provide equal access to oral therapies at the same out-of-pocket cost as IV, port, or injection treatments. As more lung cancer treatments become available, patients deserve affordable options that allow them to spend less time in clinics and more time living their lives.' 'Over the last 15 years, we've seen remarkable advances in lung cancer treatment, particularly in the development of new oral therapies,' said Andrea Ferris, President and CEO of LUNGevity Foundation. 'We applaud the reintroduction of the Cancer Drug Parity Act, which would improve access to innovative treatments by equalizing cost-sharing between oral and intravenous therapies. Patients should have access to the best possible care without having to worry about outdated insurance practices.' The Coalition to Improve Access to Cancer Care urges Congress to act quickly to pass the Cancer Drug Parity Act. The bill will remove financial barriers to care, support treatment innovation, and bring insurance coverage in line with the way cancer is increasingly treated today. About the Coalition to Improve Access to Cancer Care The Coalition for Improved Access to Cancer Care (CIACC) is a patient-focused organization representing patients, health-care professionals, care centers and industry committed to ensuring cancer patients have equal access to all approved cancer regimes, including (but not limited to) oral and intravenous drugs, injections, surgery, radiation, transplantation, etc. Media Contact Danielle Doheny, International Myeloma Foundation (IMF) Director of Public Policy and AdvocacyPhone: 202-531-7954 Email: [email protected]